Dr Alan Cross | Professor of Medicine
University of Maryland School of Medicine | United States

Dr Alan Cross, Professor of Medicine, University of Maryland School of Medicine

Dr. Cross is Professor of Medicine at the Institute for Global Health Center for Vaccine Development (CVD). He is trained in internal medicine and infectious diseases and has been a physician-scientist, with a primary interest in vaccine development, for over 40 years. Dr. Cross develops conjugate vaccines to prevent infection and colonization from Gram-negative bacteria including Pseudomonas aeruginosa, Klebsiella, and E. coli. Dr. Cross served in the U.S. Army at the Walter Reed Army Institute of Research for 20 years and was head of the Hospital Epidemiology Unit at Walter Reed Army Hospital. During his service, he developed a detoxified endotoxin subunit vaccine and vaccines for Pseudomonas aeruginosa, Klebsiella, and E. coli that progressed to Phase 3 clinical studies. As Chief of the Department of Bacterial Diseases, he directed clinical studies on meningococcal and gonococcal infections and research on biodefense. After his retirement from the Army in 1994, he became Director of the Program in Infectious Diseases at the University of Maryland Greenebaum Cancer Center and member of the attending staff of the Division of Infectious Diseases. In 2003, he joined the CVD. In response to bioterrorism, the National Institutes of Health (NIH) created the Middle Atlantic Regional Centers of Excellence (MARCE) where Dr. Cross was co-leader of the Tularemia and later Mucosal Biology Research Programs. Dr. Cross has served two rotations on the Anti-infective Drug Advisory Committee of the U.S. Food and Drug Administration (FDA), numerous special emphasis panels and a permanent study section for the NIAID and Department of Defense, an advisory committee for meningococcal vaccines at the Walter Reed Army Institute of Research, and on many data safety and monitoring committees for clinical studies sponsored by industry and the National Institutes of Health (NIH).

Appearances:



DC Co-conference Day 3 April 5 @ 09:10

Using a core endotoxin vaccine (J5) to fight the increasing spread of multidrug-resistant (MDR) gram-negative bacterial (GNB) infections

  • Directing a vaccine against the conserved LPS core (lipooligosaccharide, LOS) region of GNBs as a highly effective and protective target
  • Two Ph1 trials showing how well-tolerated and non-reactogenic the vaccine was as well as high immunogenic levels when administered with CPG 7909 adjuvant
  • Future applications to generate antibodies for the treatment of a broad range of MDR GNB infections
  • How could the vaccine affect the microbiome?

back to speakers